Company Overview
Co-Diagnostics, Inc. operates as a specialized molecular diagnostics company dedicated to the development, manufacturing, and sale of reagents essential for diagnostic tests that function through the detection and analysis of nucleic acid molecules within the United States and international markets. The enterprise is positioned within the broader Healthcare sector, specifically functioning inside the Medical Devices industry, where it provides critical infrastructure for laboratories seeking to identify specific genetic markers or pathogens. The company currently maintains a market capitalization of $3.67M and employs a workforce of 132 individuals to support its global operational footprint. These figures indicate that the company operates with a relatively small market capitalization relative to its annual revenue of $507,892, suggesting a niche operational scale that relies heavily on capital efficiency rather than massive top-line volume to sustain its business model.
Financial Health
The company reported trailing twelve-month revenue of $507,892, yet this top-line figure masks a significant operational challenge, as the net income for the same period was -$32,181,404, resulting in a massive disparity that reveals a highly volatile or structurally high cost structure where expenses far exceed revenue generation. This divergence is further highlighted by an EBITDA of -$34,334,228, indicating that even before interest and taxes, the core business operations are generating substantial losses that must be covered by external financing or asset liquidation. Free cash flow stands at -$20,499,544, which signifies a negative cash generation capability that severely limits the company's financial flexibility and its ability to fund operations or invest in R&D without continuous external capital injections. The gross margin is reported at 34.0%, which suggests that the cost of goods sold consumes roughly two-thirds of revenue, while the operating margin of -4824.5% and profit margin of 0.0% indicate that overhead costs and other operating expenses are disproportionately high relative to sales, erasing all profitability. On the balance sheet, the company holds $11.44M in cash against $1.47M in debt, creating a superficially strong liquidity position, although the debt-to-equity ratio of 3.70 suggests a highly leveraged capital structure that exposes the firm to significant risk if cash reserves are depleted. The current ratio of 3.81 indicates that the company possesses more than three times the current assets needed to cover its short-term liabilities, pointing to robust short-term liquidity despite the underlying operational losses. Furthermore, the return on equity is -62.1% and the return on assets is -37.9%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the business or the assets utilized to generate revenue.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the negative earnings, while the forward P/E is reported as -0.14, implying that the market anticipates continued negative earnings in the near term rather than a transition to profitability. The price-to-book ratio stands at 0.07, which indicates that the market values the company at less than one-tenth of its net asset value, suggesting a deep discount to book value rather than a premium. Additionally, the price-to-sales ratio is 7.22 and the EV/EBITDA is 0.19; these alternative valuation multiples suggest that the stock is priced based on revenue multiples given the lack of earnings, while the extremely low EV/EBITDA reflects the massive negative earnings multiple embedded in the current share price. The stock has experienced extreme volatility over the past year, trading between a 52-week high of $46.50 and a 52-week low of $1.66, meaning the current price sits significantly below the recent peak and near the bottom of its annual trading range. With a beta of 1.40, the company exhibits price volatility that is 40% higher than the broader market, indicating that share prices are likely to swing with greater intensity than the general market index during periods of market movement.
Growth & Income
The company experienced a revenue growth of -77.3% year-over-year, while earnings growth is listed as N/A due to the absence of positive earnings in the prior period, a situation where the contraction in revenue is directly driving the deepening losses rather than a divergence in growth rates between the top line and bottom line. As a non-dividend payer, the company does not offer a dividend yield or a payout ratio, as these metrics are N/A or 0.0% respectively, which means the company retains all available cash flows to potentially fund operations or pay down debt rather than distributing income to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a complete lack of current income distribution, reflecting a business stage focused on survival or potential restructuring rather than expansion or shareholder returns.